{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:04:19Z","timestamp":1783127059162,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T18:18:56Z","timestamp":1737829136000},"page":"494-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA\/GEM Transplantation Trials"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1752-3081","authenticated-orcid":false,"given":"David F.","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel T.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"I\u00f1igo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-1318","authenticated-orcid":false,"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi L\u00f3pez","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez de la Gu\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Calasanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa Mart\u00edn","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-9570","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2025.01.014_bib0001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-019-0199-3","article-title":"Deciphering the chronology of copy number alterations in Multiple Myeloma","volume":"9","author":"Aktas Samur","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2025.01.014_bib0002","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","article-title":"Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2025.01.014_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.clml.2025.01.014_bib0004","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","article-title":"Impact of acquired del(17p) in multiple myeloma","volume":"3","author":"Lakshman","year":"2019","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2025.01.014_bib0005","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.clml.2025.01.014_bib0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2002-08-2436","article-title":"Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants","volume":"101","author":"Avet-Loiseau","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.01.014_bib0007","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.01.014_bib0008","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403091","article-title":"t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma","volume":"17","author":"Garand","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.01.014_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.01.014_bib0010","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.01.014_bib0011","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/bjh.17627","article-title":"Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma","volume":"195","author":"Bal","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.01.014_bib0012","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13325","article-title":"Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?","volume":"103","author":"Gran","year":"2019","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.01.014_bib0013","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bbmt.2018.11.003","article-title":"Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"25","author":"Takamatsu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.01.014_bib0014","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2013.05.017","article-title":"Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma","volume":"19","author":"Sasaki","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.01.014_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-023-00807-9","article-title":"Multiple myeloma with t(11;14): impact of novel agents on outcome","volume":"13","author":"Puertas","year":"2023","journal-title":"Blood Cancer J"},{"issue":"32","key":"10.1016\/j.clml.2025.01.014_bib0016","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of Venetoclax plus Daratumumab and Dexamethasone, with or without Bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.clml.2025.01.014_bib0017","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2025.01.014_bib0018","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.01.014_bib0019","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.01.014_bib0020","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.01.014_bib0021","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.01.014_bib0022","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.014_bib0023","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1182\/blood-2018-99-119051","article-title":"Outcomes of Myeloma patients with t(11;14) receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) induction therapy","volume":"132","author":"Kaufman","year":"2018","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.01.014_bib0024","doi-asserted-by":"crossref","first-page":"8064","DOI":"10.1200\/JCO.2022.40.16_suppl.8064","article-title":"Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy","volume":"40","author":"Pirmohammed","year":"2022","journal-title":"JCO"},{"issue":"18","key":"10.1016\/j.clml.2025.01.014_bib0025","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.01.014_bib0026","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.clml.2025.01.014_bib0027","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.01.014_bib0028","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.01.014_bib0029","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.clml.2025.01.014_bib0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2025.01.014_bib0031","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood-2019-126867","article-title":"Outcomes of patients with t(11;14) multiple myeloma: an International Myeloma Working Group multicenter study","volume":"134","author":"Kumar","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.01.014_bib0032","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.12633","article-title":"AT -101 downregulates BCL 2 and MCL 1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and W aldenstr\u00f6m macroglobulinaemia","volume":"164","author":"Paulus","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:25Z","timestamp":1762600645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000242"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA\/GEM Transplantation Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}